{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-211918","form_type":"8-K","ticker":"ALEC","cik":"0001653087","company_name":"Alector, Inc.","filed_at":"2026-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.671512+00:00","generated_at":"2026-05-14T21:49:44.024741+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Alector Q1 net loss $22.9M ($0.21/sh); discontinues Phase 2 nivisnebart trial after futility","bullets":["Net loss of $22.9M ($0.21/sh) vs $40.5M ($0.41) in Q1 2025; revenue $1.0M down from $3.7M.","Cash, cash equivalents, and investments $206.5M; runway expected through at least 2027.","Discontinued Phase 2 PROGRESS-AD trial of nivisnebart (AL101) in early AD after futility analysis.","ABC platform progress: AL037/AL137 (anti-Aβ) targeting IND in Q1 2027; AL050 (GCase ERT for PD) preclinical; AL164 (Tau siRNA) in IND-enabling studies.","R&D expenses decreased to $17.9M from $33.6M; G&A $8.1M from $14.7M due to workforce reductions."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-211918","json":"https://secwatch.observer/filing/0001193125-26-211918.json","markdown":"https://secwatch.observer/filing/0001193125-26-211918.md","text":"https://secwatch.observer/filing/0001193125-26-211918.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1653087/000119312526211918/0001193125-26-211918-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1653087/000119312526211918/alec-20260507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T21:49:44.024741+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"378a929c243442fd2e02b79ff021e637c7fdaf83","claim":"Alector, Inc. reported the quarter ended March 31, 2026 results: revenue $1.0 million, net income $22.9 million, EPS $0.21 per share.","evidence_excerpt":"Revenue. Collaboration revenue for the quarter ended March 31, 2026, was $1.0 million, compared to $3.7 million for the same period in 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1653087/000119312526211918/0001193125-26-211918-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2026"},{"label":"Revenue","value":"$1.0 million"},{"label":"Net income","value":"$22.9 million"},{"label":"EPS","value":"$0.21 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}